Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
BLS Pharmaceuticals's cash receipts from operating activities for the
six
months ended in Dec. 2025 was A$32.37 Mil.
2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.
BLS Pharmaceuticals's cash payments for the
six
months ended in Dec. 2025 was A$-33.64 Mil.
3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.
BLS Pharmaceuticals's cash payments for the
six
months ended in Dec. 2025 was A$0.00 Mil.
4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.
BLS Pharmaceuticals's cash payments for the
six
months ended in Dec. 2025 was A$0.00 Mil.
5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.
BLS Pharmaceuticals's cash payments for the
six
months ended in Dec. 2025 was A$-0.10 Mil.
6. Interest Received:
It represents interest received by the company in the direct cash flow method.
BLS Pharmaceuticals's cash payments for the
six
months ended in Dec. 2025 was A$0.08 Mil.
7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.
BLS Pharmaceuticals's cash payments for the
six
months ended in Dec. 2025 was A$0.00 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).
BLS Pharmaceuticals's cash flow from others for the
six
months ended in Dec. 2025 was A$0.00 Mil.
BLS Pharmaceuticals Cash Flow from Operations Related Terms
BLS Pharmaceuticals Cash Flow from Operations Historical Data
* Premium members only.
The historical data trend for BLS Pharmaceuticals's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLS Pharmaceuticals Cash Flow from Operations Chart
BLS Pharmaceuticals Cash Flow from Operations Calculation
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
BLS Pharmaceuticals's Cash Flow from Operations for the fiscal year that ended in Jun. 2025 is calculated as:
Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Operations of A$2.03 Mil mean?
BLS Pharmaceuticals (ASX:BLS) has a Cash Flow from Operations of A$2.03 Mil as of Dec. 2025. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for BLS Pharmaceuticals and its competitors.
Is BLS Pharmaceuticals' Cash Flow from Operations too high?
BLS Pharmaceuticals' current Cash Flow from Operations is A$2.03 Mil. Overall, BLS Pharmaceuticals has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does BLS Pharmaceuticals' Cash Flow from Operations compare to KHC and GIS?
BLS Pharmaceuticals' Cash Flow from Operations of A$2.03 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Biotechnology company?
A good Cash Flow from Operations depends on the Biotechnology industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for BLS Pharmaceuticals and its competitors. BLS Pharmaceuticals's current Cash Flow from Operations is A$2.03 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BLS Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, BLS Pharmaceuticals (ASX:BLS) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.69, compared to a current price of A$0.97 — trading 40.6% above its estimated fair value. The current Cash Flow from Operations is A$2.03 Mil. BLS Pharmaceuticals' overall GF Score™ is 46/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For BLS Pharmaceuticals (ASX:BLS), the current Cash Flow from Operations is A$2.03 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BLS Pharmaceuticals (ASX:BLS) Overvalued in 2026?
Based on GuruFocus' analysis, BLS Pharmaceuticals stock appears to be overvalued.
The current stock price of A$0.97 is trading 40.6% above its estimated GF Value™ of A$0.69.
GuruFocus considers BLS Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:BLS:
Cash Flow from Operations: A$2.03 Mil
GF Value™: A$0.69 vs. price of A$0.97 (40.6% above fair value)
No single metric tells the full story. See the ASX:BLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bioxyne Ltd is an Australian life science and health products company. The company is engaged in the development, manufacture, and distribution of consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus fermentum PCC. Some of its products include Breathe Life Science, Dr Watson, BLS Clinics, Mirai Solution, CanXChange, and others. The company operates in segments, namely, Pharmaceutical manufacture and wholesale supply (business to business), Manufacture and distribution (wholesale, online, and retail), and Wholesale of patented Probiotics.
46GF Score
Get the complete analysis for ASX:BLS
Cash Flow from Operations is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BLS has been successfully added to your 
